BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Lupin Ltd. is a multinational pharma company engaged in manufacturing and marketing branded and generic formulations, active pharma ingredients, biotech products as well as over-the-counter medicines across multiple dosage forms and therapeutic categories.
Establishment inspection report for the Goa facility (with voluntary action initiated status) could provide a significant respite in Lupin’s intense drive to address pending compliance issues (still some way to go). The U.S. contributed 38% of total revenues in FY21.
Also, to add to Lupin’s woes, for the last four years the U.S. Food and Drug Administration compliance track record has been inconsistent.
The Goa facility has ~20 odd pending abbreviated new drug applications according to management commentary from earlier earnings calls.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR